Several different putative predictive factors for anti-PD-L1 and anti-PD-1 therapies have been reported, including expression of PD-L1 itself, either on cancer cells, tissue or circulating immune effector cells [37, 38]. This evidence concerns the gene PDCD1 and cancer.